4-cholesten-3-one decreases breast cancer cell viability and alters membrane raft-localized EGFR expression by reducing lipogenesis and enhancing LXR-dependent cholesterol transporters.

Josiane EliaDelphine CarbonnelleCédric LogéLucie OryJean-Michel HuvelinMona TannouryMona Diab-AssafKarina PetitEl-Hassane Nazih

Published in: Lipids in health and disease (2019)

Our results show that 4-cholesten-3-one exerts promising antitumor activity by altering LXR-dependent lipid metabolism in breast cancer cells without increasing lipogenesis.

Keyphrases

breast cancer cells
small cell lung cancer
poor prognosis
high fat diet induced
epidermal growth factor receptor
type diabetes
fatty acid
binding protein
insulin resistance
metabolic syndrome
young adults
long non coding rna